Statins and biomarkers in claudicants with peripheral arterial disease: Cross-sectional study

Vascular

Volumn 14, Issue 4, 2006, Pages 193-200

  DePalma, Ralph G ^a,b   Hayes, Virginia W ^b   May, Patricia E ^b   Cafferata, H Treat ^a   Mohammadpour, Hamid A ^b   Brigg, Laura A ^b   Chow, Bruce K ^c   Shamayeva, Galina ^c   Zacharski, Leo R ^d  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b VA Sierra Nevada Health Care System   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Atherosclerosis; C reactive protein; Cytokines; Inflammatory markers

Indexed keywords

ATORVASTATIN; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; FERRITIN; FLUINDOSTATIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR;

ADULT; ARTERY DISEASE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; CYTOKINES; FEMALE; FERRITINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-6; INTERMITTENT CLAUDICATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERIPHERAL VASCULAR DISEASES; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846207118     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.2310/6670.2006.00039     Document Type: Article

References (29)

1. Ridker PM, Cannon CP, Marrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352: 20-8.
2. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38.
3. Cannon CP, Marrow D, Rafai N, et al. Lower C-reactive protein levels have better clinical outcomes after statin therapy. Available at: www.cardiologyonline.com/journal_articles/Lower_C_reactive. htm (accessed Jan 12, 2005).
4. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344:1959-65.
5. DePalma RG, Hayes VW, Cafferata HT, et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003;111:215-21.
6. Waehre T, Damas JK, Gullestad L, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003;41:1460-7.
7. Monaco C, Rossi E, Milazzo D, et al. Persistent systemic inflammation is largely unrelated to the atherothrombotic burden. J Am J Cardiol 2005;45:238-43.
8. Howes PS, Zacharski LR, Sullivan J, Chow B. Role of stored iron in atherosclerosis. J Vasc Nurs 2000;18:109-16.
9. Gerlag DM, Ransone L, Tak PP, et al. The effect of T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000;165:1652-8.
10. Charles P, Elliott MJ, Davis D, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFα therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
11. Nakagawa S, Koomen CW, Bos JD, Teunissen MBM. Differential modulation of human epidermal Langerhans cell maturation by ultraviolet B radiation. J Immunol 1999;163:5192-200.
12. Mizia-Stec K, Zahorska-Markiewicz B, Gasior Z. Cigarette smoking and inflammatory indices in coronary artery disease. Int J Cardiol 2004;93:169-74.
13. Fernandez-Real JM, Vayreda M, Casamitjana R, et al. Circulating granulocyte-macrophage colony-stimulating factor and serum fatty acid composition in men and women. Metabolism 2001;50:1479-83.
14. Spranger J, Kroke A, Möhlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Diabetes 2003;52:812-7.
15. Brevetti G, Silvestro A, Di Giacomo S, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vasc Surg 2003;38:374-9.
16. Enstrom J, Site-Flondell D, Lindblad B, et al. Risk of treatment of peripheral arterial disease is related to inflammation-sensitive plasma proteins: a prospective cohort study. J Vasc Surg 2004;40: 1101-5.
17. Unlu Y, Karapolat S, Karaca Y, Kiziltunc A. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb Res 2005. [Epub ahead of print].
18. Brevetti G, Piscione F, Silvestro O, et al. Increased inflammatory status and higher prevalence of three-vessel coronary artery disease in patients with concomitant coronary and peripheral atherosclerosis. Thromb Haemost 2003;89:1058-63.
19. Ridker PM, Rifai N, Pfeffer M. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;100: 230-5.
20. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cervastatin among 785 patients with hypercholesterolemia. Circulation 2001;103:1191-3.
21. Schillinger M, Exner M, Mlekusch W, et al. Statin theapy improves cardiovascular outcome of patients with peripheral vascular disease. Eur Heart J 2004;25:742-8.
22. Blann AD, Gurney D, Hughes E, et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral vascular disease. Am J Cardiol 2001;88:89-92.
23. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000;10: 1767-72.
24. Ridker PM, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation 2000;101:2149-53.
25. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138(5pt 2):S419-20.
26. Frostegard J, Ulfgren A-K, Nyberg P, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999;145:33-43.
27. Valdez CA, Ulrich H. Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. J Manag Care Pharm 2005;11:499-504.
28. Chen YG, Xu F, Zhang Y, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl) 2006;119:32-6.
29. Biasucci LM, Liuzzo G, Colizzi C, Maseri A. The role of cytokines in unstable angina. Exp Opin Investig Drugs 1998;10:1667-72.